M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer Pharmaceutical TechnologySolstice Oncology has secured $225m to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.OncologyRead full story pharminent September 10, 2026 (Last updated: September 10, 2026) Pharmaceutical Technology Solstice Oncology has secured $225m to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy. Oncology Read full story Post navigation Previous: FDA Names Permanent CDER and CBER Directors While the Commissioner’s Post Awaits ConfirmationNext: HHS appoints permanent FDA CBER, CDER heads Related Stories M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026 M&A / Deals Boehringer signs AI drug discovery deal with Owkin pharminent September 3, 2026